Matches in Nanopublications for { ?s ?p "[These results show for the first time that TGF-beta2, its receptors TGF-beta R1 and TGF-beta R2, and activator thrombospondin-1 are concordantly suppressed early in breast carcinogenesis by histone modifications and indicate that the TGF-beta signaling pathway is a novel target for gene activation by epigenetic therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 8 of
8
with 100 items per page.
- NP632165.RAdUUB9Whwv9mwh4fKV4ROKtatN4muafh8x2TM-sO0RdI130_assertion description "[These results show for the first time that TGF-beta2, its receptors TGF-beta R1 and TGF-beta R2, and activator thrombospondin-1 are concordantly suppressed early in breast carcinogenesis by histone modifications and indicate that the TGF-beta signaling pathway is a novel target for gene activation by epigenetic therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP632165.RAdUUB9Whwv9mwh4fKV4ROKtatN4muafh8x2TM-sO0RdI130_provenance.
- NP919070.RArCFWBleHfSDMH6mHv1r7ka4FZZ1wrk_q7LG2zD5G3ec130_assertion description "[These results show for the first time that TGF-beta2, its receptors TGF-beta R1 and TGF-beta R2, and activator thrombospondin-1 are concordantly suppressed early in breast carcinogenesis by histone modifications and indicate that the TGF-beta signaling pathway is a novel target for gene activation by epigenetic therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP919070.RArCFWBleHfSDMH6mHv1r7ka4FZZ1wrk_q7LG2zD5G3ec130_provenance.
- NP656989.RAJXBshuKnQO3BsQ60IBJcp82804hLgeeGMfVItw3DDy8130_assertion description "[These results show for the first time that TGF-beta2, its receptors TGF-beta R1 and TGF-beta R2, and activator thrombospondin-1 are concordantly suppressed early in breast carcinogenesis by histone modifications and indicate that the TGF-beta signaling pathway is a novel target for gene activation by epigenetic therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP656989.RAJXBshuKnQO3BsQ60IBJcp82804hLgeeGMfVItw3DDy8130_provenance.
- assertion description "[These results show for the first time that TGF-beta2, its receptors TGF-beta R1 and TGF-beta R2, and activator thrombospondin-1 are concordantly suppressed early in breast carcinogenesis by histone modifications and indicate that the TGF-beta signaling pathway is a novel target for gene activation by epigenetic therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[These results show for the first time that TGF-beta2, its receptors TGF-beta R1 and TGF-beta R2, and activator thrombospondin-1 are concordantly suppressed early in breast carcinogenesis by histone modifications and indicate that the TGF-beta signaling pathway is a novel target for gene activation by epigenetic therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[These results show for the first time that TGF-beta2, its receptors TGF-beta R1 and TGF-beta R2, and activator thrombospondin-1 are concordantly suppressed early in breast carcinogenesis by histone modifications and indicate that the TGF-beta signaling pathway is a novel target for gene activation by epigenetic therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP645921.RAYHY7FuMZJ_sy-p3P72l6Gd0ZUS-oNSPFW3HtmFKu3bc130_assertion description "[These results show for the first time that TGF-beta2, its receptors TGF-beta R1 and TGF-beta R2, and activator thrombospondin-1 are concordantly suppressed early in breast carcinogenesis by histone modifications and indicate that the TGF-beta signaling pathway is a novel target for gene activation by epigenetic therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP645921.RAYHY7FuMZJ_sy-p3P72l6Gd0ZUS-oNSPFW3HtmFKu3bc130_provenance.
- NP736231.RAPPr_OaDsYoFuDZtrJYi3sBK0hv7LAWITUIGUNnl1eQM130_assertion description "[These results show for the first time that TGF-beta2, its receptors TGF-beta R1 and TGF-beta R2, and activator thrombospondin-1 are concordantly suppressed early in breast carcinogenesis by histone modifications and indicate that the TGF-beta signaling pathway is a novel target for gene activation by epigenetic therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP736231.RAPPr_OaDsYoFuDZtrJYi3sBK0hv7LAWITUIGUNnl1eQM130_provenance.